Wednesday, GSK Plc GSK reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and up 4% on constant currency. The analysts estimated sales of $9.58 billion.Vaccine sales fell 14% (-11% at constant currency) to 2.21 billion pounds, primarily impacted by lower demand for Arexvy related to a more limited ACIP recommendation in the U.S. and channel inventory consumption compared to launch year stocking in 2023. Arexvy sales reached 158 million pounds, down 70%.Menin ...

GSK plc (GSK) recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab in two respiratory indications – asthma with type II inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP).With regard to the asthma indication, the GSK submission seeks approval for the drug in individuals aged 12 years and older. Concerning CRSwNP, GSK intends to secure approval in adults. Similar regulatory filings for the drug have also been validated for review i ...

GSK plc (GSK) announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary, advanced or recurrent endometrial cancer.The regulatory body has now approved Jemperli in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with primary, advanced or recurrent endometrial cancer who are candidates for systemic therapy in the European Union (“EU”).The approval ...

Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More Generative AI has become a key piece of infrastructure in many industries, and healthcare is no exception. Yet, as organizations like GSK push the boundaries of what generative AI can achieve, they face significant challenges — particularly when it comes to reliability. Hallucinations, or when AI models generate incorrect or fabricated information, are a persistent problem in high-s ...

Company Overview - GSK is a global biopharma company focused on the prevention and treatment of disease [5] - The company demerged its consumer business three years ago to create a dedicated biopharma company with a clear focus on benefiting patients and shareholders [3] Financial Performance - For the full year 2024, GSK confirmed sales growth guidance of 7% to 9% and core operating profit growth of 11% to 13% [2] - In the first nine months of 2024, GSK delivered 9% sales growth and 19% core operating profit growth, reflecting strong momentum in Specialty Medicines and overall portfolio resilience [5] Strategic Outlook - GSK expects to secure five product approvals in 2025 [2] - The company has high confidence in delivering the growth outlooks set for 2026 and 2031 [2]

Key Points Company and Industry Overview 1. **GSK as a Global Biopharma Company**: GSK is a global biopharma company focused on the prevention and treatment of disease [3]. 2. **Demerger and Biopharma Focus**: GSK demerged its consumer business three years ago, creating a dedicated biopharma company with a clear focus on benefiting patients and shareholders [2]. Financial Performance 3. **2024 Sales and Profit Growth**: In the first nine months of 2024, GSK delivered 9% sales growth and 19% core operating profit growth [3]. 4. **Full-Year 2024 Guidance**: GSK confirmed its guidance for full-year 2024, expecting sales growth of 7% to 9% and core operating profit growth of 11% to 13% [5]. Product Approvals and Outlook 5. **Product Approvals and Growth Outlook**: GSK expects to secure five product approvals in the coming year and remains highly confident in delivering the growth outlooks set for 2026 and 2031 [5].

GSK plc (GSK) announced that the FDA has granted a Breakthrough Therapy Designation to its investigational B7-H3-targeted antibody-drug conjugate (ADC), GSK5764227 (GSK’227), for the treatment of relapsed or refractory osteosarcoma in adult patients whose disease progressed on at least two prior lines of therapy.The FDA grants Breakthrough Therapy designation to expedite the development and review of therapies for severe or life-threatening diseases where preliminary clinical evidence shows that the therapy ...

GSK plc’s (GSK) HIV subsidiary, ViiV Healthcare announced that the Europe Medicines Agency’s (“EMA”) Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion recommending marketing authorization for its new long-acting HIV regimen.ViiV Healthcare is a global specialist HIV company, majorly owned by GSK with Pfizer (PFE) and Shionogi as shareholders.ViiV Healthcare was formed by GSK and Pfizer in 2009.The CHMP recommended marketing authorization to Vocabria (cabotegravir long-a ...

GSK (GSK) stock has declined 20.2% in the past three months compared with a decrease of 12.3% for the industry. The stock has also underperformed the sector and the S&P 500 index, as seen in the chart below. The stock is also trading below its 200 and 50-day moving averages.GSK Stock Underperforms Industry, Sector and S&PImage Source: Zacks Investment ResearchGSK enjoys a strong position in HIV and Vaccines therapeutic areas. The spin-off of the Consumer unit in 2022 has allowed it to focus on drug developm ...

GSK plc (GSK) announced that the European Commission (EC) has approved a single-vial, fully liquid presentation of its meningococcal vaccine, Menveo (MenACWY) for active immunization in children aged two years, adolescents as well as adults.The single-vial, fully liquid presentation of Menveo is likely to simplify the vaccination process against invasive meningococcal disease (IMD) caused by bacterial serogroups A, C, W and Y.The fully liquid presentation of the vaccine will help healthcare providers with a ...